# Joaquim Bellmunt

Source: https://onco.cc/people/joaquim-bellmunt/  
OnCo record `joaquim-bellmunt` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led KEYNOTE-045, the first trial to show immunotherapy beats chemotherapy in advanced bladder cancer.

## Summary

Joaquim Bellmunt was principal investigator of KEYNOTE-045, which showed pembrolizumab improves survival over second-line chemotherapy in platinum-refractory urothelial cancer, the first randomised survival benefit for immunotherapy in the disease. He developed the Bellmunt prognostic score and led the vinflunine and TCGA bladder subtype work. He directs the bladder cancer centre at Dana-Farber.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: urothelial; immunotherapy
- Role: Director, Bladder Cancer Center, Dana-Farber Cancer Institute; Associate Professor, Harvard Medical School
- Specialisms: Urothelial cancer; Immunotherapy; Chemotherapy; Molecular subtypes

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Bellmunt%20J%5BAuthor%5D%20urothelial%20pembrolizumab

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)

---
JSON: https://onco.cc/api/v1/entities/joaquim-bellmunt.json